Sign in to view Rekha’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
San Francisco Bay Area
Contact Info
Sign in to view Rekha’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
4K followers
500+ connections
Sign in to view Rekha’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Rekha
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Rekha
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Sign in to view Rekha’s full profile
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Languages
-
English
-
-
Hindi
-
Organizations
-
Life Science Council, Springboard Enterprises
Executive Committee Member
View Rekha’s full profile
Sign in
Stay updated on your professional world
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Other similar profiles
-
Kristen Fortney
United StatesConnect -
Peng Leong
San Francisco, CAConnect -
Eric Morgen
San Francisco Bay AreaConnect -
Julia Owens
Ann Arbor, MIConnect -
Ciara Kennedy
Salt Lake City, UTConnect -
Shehnaaz Suliman, M.D. (MB ChB), M.B.A., M.Phil.
San Mateo, CAConnect -
Wendye Robbins
Boston, MAConnect -
Emily Drabant Conley
San Francisco Bay AreaConnect -
Sheila Gujrathi, MD
Biotech Executive | Physician Scientist | Healthcare Investor | Drug Developer
San Diego, CAConnect -
June Lee, MD FACCP
San Francisco, CAConnect -
BJ Sullivan, PhD
New York, NYConnect -
Dominique Verhelle
Boston, MAConnect -
Leslie J Williams
Boston, MAConnect -
Yasir Al-Wakeel
Palo Alto, CAConnect -
Alice Zhang
San Francisco, CAConnect -
Stephen Hurly
Philadelphia, PAConnect -
Jeb Keiper
Cambridge, MAConnect -
Kenneth Moch
Chapel Hill, NCConnect -
Jeff Goater
Greater BostonConnect -
Steve Zarrilli,CPA
United StatesConnect
Explore more posts
-
John F. Heerdink, Jr.
Marc-Henry PITTY, MD, CEO of Oregon Therapeutics, "To date, our first-in-class #metabolicinhibitor, XCE853, has exhibited robust preclinical efficacy in both in vitro and in vivo models across multiple #cancer types. Lantern’s (NASDAQ: LTRN) #RADR®AI platform will leverage the in vitro and in vivo data to potentially advance XCE853 development in a highly targeted manner and will help inform disease indications and #biomarker signatures that can aid in the design of future #clinicaltrials and in the pursuit of combination therapies with other approved cancer drugs. Our team is looking forward to efficiently selecting among the landscape of ideal development options and efficiently de-risking future clinical development decisions." https://lnkd.in/g8XPQSsa #biotech #france #texas #oncology #artificialIntelligence
6 -
Bryan Kennedy
According to the latest analysis from BiopharmIQ by Amp, Pennsylvania holds the #3 position in CGT ecosystems for companies with under 50 employees. However, as these companies grow, I hope they choose to mature in Philadelphia. Recently, I've had numerous conversations about the region's shortage of leadership/ executive talent. It's intriguing considering that 80% of Big Pharma is located within 90 miles of the city. What the CGT sector needs is more experienced leadership, and Big Pharma could serve as an excellent source for it. For the latest updates on Life Science and Biotech news in the Philadelphia region, join The Informal Philadelphia Life Science Group below!
3 -
Abhishek Jha
Despite challenges in the IPO market in 2021, the biotechnology sector is resilient and showing signs of recovery. Tempus led the way last week. Congratulations to all stakeholders at Tempus! This period of turbulence urges biotech firms to strategically focus on building strong data foundations, which will not only attract investments but also pave the way for sustainable growth and innovation. Embracing uncertainty as an opportunity for innovation and skill development could redefine leadership in biotech, fostering a culture of resilience and adaptability crucial for sustained success in a rapidly evolving industry landscape. #Biotech #Leadership
19 -
Nick Hutchinson
Roche's recent decision to offload their Vacaville facility highlights the increasing importance of cell line productivity in biomanufacturing strategy. According to Dan Stanton of Bioprocess Insider, Roche is moving towards more high titer processes and products with lower volume demands. (You can read the article here https://lnkd.in/erRx597k) Agile manufacturing strategies are enabled by cell line productivity, which allows for the same amount of drug substance to be produced in smaller bioreactors. This, in turn, allows for smaller clean rooms and lower running costs. Just - Evotec Biologics' J.CHO High Expression System cell lines, grown in perfusion bioreactors, produce over 4 g/L of antibody each day, equivalent to around 30 g/L in fed-batch mode (https://lnkd.in/eexeJrQA). This level of productivity allows for commercial quantities of antibody to be manufactured in 1000L single-use bioreactors in our modular J.POD facilities. As a result, large-scale stainless-steel facilities are becoming redundant. The future of biomanufacturing lies in maximizing cell line productivity, and our J.CHO system is leading the way. #biomanufacturing #celllineproductivity #JCHO #JPod #agilemanufacturing 👨⚕️Philip Boehme
36 -
Adrian Rubstein
T cell supercharging for solid tumors - CRISPR meets Cell therapy A new biotech OverT Bio is coming out of stealth with $16 million from The round was co-led by ARTIS Ventures and Wing VC, with participation from Fusion Fund, OMX Ventures, Alexandria Venture Investments, Gaingels, Civilization Ventures, Hawktail, and Cancer Research Institute (CRI). Here are 5 things investors should know about it. 1. Addressing the Solid Tumor Challenge: The holy grail of cell therapy has been conquering solid tumors. Unlike blood cancers, these tumors present a tougher target due to their complex microenvironment. OverT's focus is significant because current success stories are rare. There are currently 1,111 trials in Phase 1, 511 in phase 2 and 12 in Phase 3 for solid tumors according to ClinicalTrials.gov. Only one cell therapy has been approved for a solid tumor cancer: Iovance’s tumor-infiltrating lymphocyte-based therapy #Amtagvi, which won FDA approval in February for advanced melanoma. 2. Supercharging T Cells with CRISPR Screens: This is where OverT's technology gets exciting. CRISPR screening allows them to identify genes that, when overexpressed, enhance T cell function against tumors. Think of it as giving T cells superpowers! This approach holds promise for creating more potent CAR-T therapies. 3. Not the Only Player in the Arena: Competition is fierce in the CAR-T space. While OverT's approach is promising, it's important to be aware of other players using similar CRISPR activation screens Sidi Chen team and Alex Marson team. 4. Diversifying the Arsenal: Gamma Delta T Cells: OverT is exploring using gamma delta T cells in their therapy. These unique immune cells are activation-independent, potentially offering an advantage over traditional T cells. This adds another layer of potential differentiation for OverT. Gamma delta T cells make up only a small percentage of circulating T cells (around 5%), but they offer some advantages like the ability to recognize tumor-associated antigens without prior MHC presentation. 5. Aggressive Timeline for Clinical Trials: OverT aiming for a mid-2025 clinical trial candidate is ambitious but demonstrates their commitment to rapid development. However, it's crucial to remember that the road from preclinical studies to market is long and fraught with risk. What do you think about this new approach to cell therapy? Spencer Knight Cookie Yu, PhD Nimisha Gupta, Ph.D. Share this news with your investor buddies. They’ll thank you later. 🗣️ #biotech #investment #investor #vc #drug #discovery #healthcare #market #business #crispr #celltherapy _________________________________________________________________________________ Biotech investor or innovator? We assist investors unlock potential by assisting with due diligence and companies refine strategies for success and get bigger exposure to investors. Send me a DM and let´s connect Follow me, hit the 🔔 Adrian Rubstein
94 -
Moonwalk Biosciences
Great to catch up with Ron Leuty at San Francisco Business Times at #BIO2024: When Moonwalk Biosciences Inc. CEO Alex Aravanis MD PhD started his presentation at the BIO convention in San Diego earlier this week, he saw a standing-room-only crowd, and after his 15-minute talk he was peppered with questions. In more formal meetings with potential partners, Aravanis faced more questions. "I think there's a lot of people who are curious about (epigenetics)" — how DNA modifications can be passed cell to cell — "curious about the capabilities, how mature it is," Aravanis said. "In the partnering meetings, there're folks who have an immediate use for it, and there are folks who said, 'Look, we reached out to you because we realized this is an exciting new area.'" The ability to spread a company's scientific message with hundreds, if not thousands, of people in a few days is why companies come to the Biotechnology Innovation Organization's annual convention, which closes today in San Diego. More than 20 Bay Area life sciences companies were scheduled among the scores making formal presentations in tiny "theaters" on the convention's exhibit floor, such as South San Francisco's Moonwalk, or in BIO's "Startup Stadium." Read the article (subscription required): https://lnkd.in/eTEdgDEa
28 -
Scott L. Rakestraw
In Episode 3 of the "Brain Cancer Science Talk" series on #MissionGBM, we chat with John de Groot, MD (Division Chief of Neuro-Oncology, UCSF) about immunotherapies, the need for combination protocols, Focused Ultrasound, and necessary improvements to clinical trial design and Regulatory framework to advance the development of treatment options for #braincancer patients. #FUS #ImmunoOncology #GBM #Onward #Nof1onBehalfofAll
34 -
Vijay Pande, PhD
By leveraging AI with vast genetic databases, we are not only quickening the pace of identifying potential drug targets but also enhancing the accuracy of clinical diagnostics and predictive modeling. Recently, I had the privilege of discussing the profound impact AI is having on pharmaceutical R&D with Kim Branson, GSK's SVP Global Head of Artificial Intelligence and Machine Learning. Listen on Raising Health: https://lnkd.in/g6QUm2-A
405 Comments -
Matt Battin
At Windhaul, we are committed to propelling growth and success for small to mid-sized clinical stage biotech companies. Our mission is straightforward: to elevate the value of biotech firms and their programs with patients, healthcare providers, and investors. Windhaul distinguishes itself as a premium boutique consulting firm and provider of innovative flexible staffing solutions leveraging highly experienced professionals. We specialize in navigating dynamic global regulatory landscapes and integrating forward thinking commercial and market access insights into the strategic decision-making process. Our team consists of seasoned industry leaders, including former c-suite executives and functional heads, who bring invaluable hands-on leadership and management expertise throughout the journey of developing and approving new therapies. Clients choose Windhaul for our immediate effectiveness and capability to seamlessly integrate expert consultants into their teams on an interim or fractional basis. Whether guiding the clinical, regulatory, or commercial development of complex biologics or cutting-edge therapies such as cell and gene editing products, Windhaul excels across the entire product lifecycle. Let's collaborate to drive innovation and create enduring value together. #Biotech hashtag #RegulatoryAffairs hashtag #CommercialStrategy hashtag #MarketAccess hashtag #DrugDevelopment hashtag #BiotechConsulting hashtag #BiotechStaffing hashtag #BiotechInvesting https://www.windhaul.com/
36 -
Bryan Kennedy
Explore our latest overview of March 2024's U.S. Biotech Funding. The top eleven private funding rounds we followed amassed $1.85 billion, contributing to a total cumulative funding of $3.76 billion. Key Highlights: >> Mirador Therapeutics led with a Series A funding of $400 million. >> Alumis secured $259 million in Series C funding. >> Sionna Therapeutics and Capstan Therapeutics followed closely with Series C and Series B funding of $182 million and $175 million respectively. >> Engrail Therapeutics concluded the top five deals with $157 million in Series B funding. >> Also included Aeovian Pharmaceuticals, Avenzo Therapeutics, Clasp Therapeutics, Rakuten Medical, Nocion Therapeutics, Inc., FogPharma Other Noteworthy Points: >> San Diego stood out as a prominent cluster, hosting headquarters for 5 of the top 11 companies that collectively secured over $1 billion in funding. >> Series A funding dominated with $750 million spread across 5 deals. >> Among the 109 investors we tracked, key players such as Alexandria Real Estate Equities, Inc., OrbiMed RA Capital Management, ARCH Venture Partners, Catalio Capital Management, Cormorant Asset Management, LP, F-Prime Capital, Farallon Capital Management, Fidelity Investments, Forbion, The Invus Group, Perceptive Advisors, Sofinnova Partners, T. Rowe Price venBio, Nextech Invest
5 -
Joey Bose
🧑💼 The Business of Biotech (2nd Edition): Gatekeepers Of Innovation 🏛️ The Food and Drug Administration (FDA) is a formidable force in the biotech industry. Here’s what it takes to be successful and avoid common mistakes that leave drug development programs stuck in the regulatory mud. ⚔️ Gatekeeper Of Innovation Traditionally, the FDA has been revered as the protector of public health and the adversary of unethical medicine. But that does not mean that it is beyond scrutiny. Congress (and the public) frequently flips between criticism of the FDA for granting approvals too quickly and then retracts and disapproves of delayed approval rates. In recent years, the public has been increasingly skeptical of the Administration as the complexity of the political relationships between other government agencies and the private sector grows. To the pharmaceutical industry, the FDA is a powerful gatekeeper that can make or break their business. The value of public and private clinical-stage companies is wholly dependent on clinical trial data and the FDA’s final stamp of approval. Clearly, intimate knowledge of the regulatory process is an absolute must for every biotech. Understand the FDA approval process like a biotech CEO: https://lnkd.in/eFZ4Uy6F #biotechnology #arthritis #osteoarthritis #investing #crowdfunding #venturecapital #healthcare #drugdevelopment #clinicaltrials #regenerativemedicine #orthopedics #orthopaedics #surgery #investor #FDA #medicine #lifesciences #researchanddevelopment #capitalmarkets
11 -
Susan B. Nichols
Artiva Biotherapeutics, a clinical-stage NK cell therapy biotech, is trying again for the public markets, it revealed Friday afternoon in an #SEC filing. The San Diego biotech is going for a Nasdaq debut but in a very different biotech financing environment than when it originally sought an #IPO in the spring of 2021, at a time when large public floats were easier to achieve thanks to low interest rates and generalist investors’ intrigue in drug development. And this time around, it’s without partner Merck, which axed their CAR-NK solid tumor collaboration last October, according to Friday’s S-1 filing. #NKcelltherapy #celltherapy #cellandgenetherapy #advancedtherapies #publicmarkets #biotech #biotechnology #financing #funding #lifescience #lifesciences #IPOs #solidtumors #bloodcancers #autoimmunedisease GC Cell 5AM Ventures venBio RA Capital Management
411 Comment -
Molly He
Just a few days after Element Biosciences celebrated its 7th anniversary of incorporation, we announced an oversubscribed series D of $277M. What a remarkable journey. In seven years, we have raised $680M, and words alone cannot express my gratitude for these groups of very special people, our team, our customers and partners, and our investors. First and foremost, our loyal, resilient and mission-driven Element team. You have persevered uncertainties, naysaying, and ambitious timelines to change how science is done and make a real impact in the world. Disrupting the norm is never easy. As RFK said: “if you are not the recipient of some derision on your path to impact change, you are probably not changing enough." Together, we have built disruptive technologies and formed an incredible company. I am so tremendously proud of you, and the best is yet to come. I am grateful for all our customers and partners, current and future. We will work with you as our long-term partners, hear your feedback, and make our products better each day. Together, we can change how science is done around the world, so that everyone has access to the best scientific tools regardless of how well they are funded. Finally, I want to thank our new and existing investors for your trust and confidence in Element. We raised these funds in the backdrop of a challenging macro-economic environment and fierce competitions in the genomics field. Element is proud to be chosen as your partner. Today marks a significant milestone in Element’s journey. With the support and dedication of our teams, customers and partners, and investors, we will continue to innovate, deliver the best solutions for our customers, and solidify our future as the next name-brand biological tools company. We are just getting started. #genomics #multiomics #innovation #grit
1,533102 Comments -
Rami Elghandour
Enjoyed discussing #dei and it’s important to building successful companies with Matthew Pillar. Especially relevant in the context of #pride month and #junteenth Diversity has and continues to be the foundation of our success at Arcellx Take a listen and let me know what you think
3 -
Susan B. Nichols
Value-based payment arrangements are crucial for expanding patient access to cell and gene therapies. That’s why I am in Washington, DC, to advocate for the Medicaid Value-based Payments for Patients (MVP) Act at the Alliance for Regenerative Medicine’s Cell & Gene Congressional Fly-In July 15-16. #CGFlyIn24 #MVPACT #celltherapy #genetherapy #cellandgenetherapy #advancedtherapies #regenerativemedicine #policy #valuebasedpayments #patientaccess #biotech #biotechnology #lifescience #lifesciences #advocacy #payments #congressionalsupport Erica Cischke #facilitatepatientaccess #removebarriers
22 -
Howard Urnovitz
Prof. Ehrlich, we found the targets for your magic bullets! We updated our video from three years ago and posted it on our new website, https://www.fbbbio.com. #venturecapital #angelinvestor #cancer #hivaids #bioOS #biotechnology #diagnostics #innovation #technology #management #startups #liquidbiopsy #neurodegenerativediseases #multiplesclerosis #parkinsonsdisease #alzheimersdisease #longhaulers #longcovid #humangenome #onetestonelife #longevity #artificialintelligence #rna #rnaseq #personalizedprevention OK
152 Comments -
Krzysztof Potempa
1/2. Biopharma dealmaking by Patricia Giglio and Amanda Micklus 2022-https://lnkd.in/d9izfipH and 2023-https://lnkd.in/d9rf_PZs. 3. 2023-Biotech back in the mainstream by John Hodgson https://lnkd.in/ddGRVWBb. Key points: "1. The public equity markets for biotech struggled during the year, with fewer than 50 initial public offerings (IPOs), a drop in follow-on offerings, and debt financing virtually non-existent. 2. Closed public markets discourage venture investment, which was down one-third on its level in 2022 and down over 50% on the recent peak of 2021. That contraction in venture capital and public equity markets made biotech financing more dependent than ever on industrial funding through partnerships or via merger and acquisitions. 3. Even though the upper threshold for venture rounds was down, four of the largest ventures round were A rounds, suggesting renewed interest in novelty. 4. Apart from Acelyrin, which flopped after clinical failure of its anti-interleukin-17 mimetic, the stock prices of the companies with largest IPOs all performed well after flotation. 5. Most notable perhaps was RayzeBio, which raised $337 million in its IPO in September for its targeted radiopharmaceutical portfolio and was acquired in December by Bristol Myers Squibb in mid-December. Its almost as if investors lined up the deal at the IPO after-party."
-
Martin Borch Jensen
The ZEPHYRUS-1 trial led by testing pamrevlumab (CTGF antibody) for #PulmonaryFibrosis published negative results yesterday, also discontinuing ZEPHYRUS-2. JAMA has a good editorial on challenges and ideas for improving predictive validity for #IPF clinical trials: - One is that the IPF label covers a heterogeneous patient population. Genetic risk factors could be used for targeting drugs, though that leaves >70% of patients with no treatment. Broader -omic characterization of patients & preclinical models could reveal which models best match patient subgroups. - Another is the FVC endpoint. Many physicians argue for more nuanced endpoints. But while we're using FVC we should think about how preclin assay map to this, given that it can't be measured in typical rodent models. Larger animals could give more direct comparisons, or when that's not feasible then we should think carefully about how anatomy and pathobiology of models reflect this endpoint. - Preclinical models for are much maligned, with high false positive rates for standard bleo mouse model. The editorial authors suggest focusing on human organoids, although this may be throwing out the baby with the bathwater: IPF is an inflammatory disease with a key role for immune cells, which aren't included in organoid/chip models (yet anyway)... We should also think about in vivo models that address the obvious limitations of the standard bleo mouse model: 1) fibrosis resolves spontaneously, instead of progressing. 2) IPF is strongly age-related, but the mice are usually young. Other species (even rats) have less spontaneous regression of fibrosis, and multiple types of injury might better capture patient exacerbations. And using older animals could capture both known and unknown mechanisms preventing normal regeneration in PF patients. Gordian Biotechnology's Vishwaraj Sontake thinks a lot about predictive validity for complex diseases like IPF. Mapping models to patients is key, and the basis for our 'Patient Avatars' concept. Trials are were biopharma spends the most dollars, so we think it's worth spending more on doing R&D in predictive models. Editorial: https://lnkd.in/gRUFQ5XK
322 Comments
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Rekha Hemrajani
1 other named Rekha Hemrajani is on LinkedIn
See others named Rekha Hemrajani